Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.

ABSTRACT:

Background and objective

The economic assessment of immuno-oncology agents in Chinese patients is limited despite a need for new therapies. Nivolumab is the first immune checkpoint inhibitor approved for the second-line treatment of non-small cell lung cancer (NSCLC) in China, and it significantly prolongs overall survival. However, considering the high cost of nivolumab, it is urgent to assess its value in China in terms of both efficacy and cost. The objective of this study was to investigate the cost-effectiveness of nivolumab vs docetaxel in the second-line setting for NSCLC patients from the Chinese healthcare system perspective.

Methods

A Markov model consisting of three health states, was designed to evaluate the lifetime cost and effectiveness of nivolumab vs docetax

SUBMITTER: Liu Q 

PROVIDER: S-EPMC6989620 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature